Catalog No.
RHB91003
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Tested applications
FCM: 1:20-1:100, IF: 1:50-1:200, IP: 1:20-1:50, WB: 1:1000-1:2000
Target
GTPase HRas, H-Ras-1, Ha-Ras, Transforming protein p21, c-H-ras, p21ras, HRAS, HRAS1, GTPase NRas, Transforming protein N-Ras, NRAS, HRAS1, GTPase KRas, K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, KRAS, KRAS2, RASK2, HRAS
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01112
Applications
FCM, IF, IP, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4 ℃ short term (1-2 weeks).
Store at -20 ℃ 12 months.
Store at -80 ℃ long term.
Clone ID
R1A94
Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312., PMID:40304209
A Child with Cutaneous-Skeletal Hypophosphatemia Syndrome Caused by a Mosaic HRAS Mutation: Outcome of Treatment with Anti-FGF23 Antibody., PMID:40295341
RBM10 loss promotes metastases by aberrant splicing of cytoskeletal and extracellular matrix mRNAs., PMID:39992626
Spitz Spindle Cell/Reed Nevus With SQSTM1 :: NTRK2 Fusion and Atypical Features in an Older Male Patient: A Case Report and Review of Literature., PMID:39980385
De novo design of Ras isoform selective binders., PMID:39975043
Elucidating the pharmacological foundations and mechanisms of the Sihai Shuyu formula in treating Graves' disease through integrated serum metabolomics and network pharmacology with molecular docking techniques., PMID:39950029
Burosumab Treatment in a Girl With Cutaneous Skeletal Hypophosphatemia Syndrome: 2-Year Follow-Up., PMID:39925163
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors., PMID:39914665
Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial., PMID:39446377
Detection and Quantitation of Endogenous Membrane-Bound RAS Proteins and KRAS Mutants in Cancer Cell Lines Using 1D-SDS-PAGE LC-MS2., PMID:39052226
Human BioMolecular Atlas Program (HuBMAP): 3D Human Reference Atlas Construction and Usage., PMID:38826261
Genetically Encoded Epoxide Warhead for Precise and Versatile Covalent Targeting of Proteins., PMID:38819260
Cytokine CCL9 Mediates Oncogenic KRAS-Induced Pancreatic Acinar-to-Ductal Metaplasia by Promoting Reactive Oxygen Species and Metalloproteinases., PMID:38731942
Therapeutic Advances and Challenges for the Management of HPV-Associated Oropharyngeal Cancer., PMID:38612819
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer., PMID:38588697
K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3., PMID:38291468
Liquid Droplet-Mediated Formulation of Lipid Nanoparticles Encapsulating Immunoglobulin G for Cytosolic Delivery., PMID:38290425
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers., PMID:38236605
Update on current diagnosis and management of anaplastic thyroid carcinoma., PMID:38179406
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma., PMID:38105998
Confirmation of canine acanthomatous ameloblastoma using RAS Q61R immunohistochemical staining of formalin-fixed paraffin-embedded tissues., PMID:37901104
Antibodies against endogenous retroviruses promote lung cancer immunotherapy., PMID:37046094
Adaptable, Turn-On Monobody (ATOM) Fluorescent Biosensors for Multiplexed Detection in Cells., PMID:37034669
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer., PMID:37020035
Simultaneous Administration of Bevacizumab with Bee-Pollen Extract-Loaded Hybrid Protein Hydrogel NPs Is a Promising Targeted Strategy against Cancer Cells., PMID:36834960
Rare molecular subtypes of lung cancer., PMID:36806787
Analysis of H-ras Mutations and Immunohistochemistry in Recurrence Cases of High-Grade Oral Squamous Cell Carcinoma., PMID:36374444
Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer., PMID:36100320
[The Effect of KRAS on Proliferation and Apoptosis of T-ALL Cell Lines]., PMID:35981360
Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer., PMID:35471938
TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model., PMID:35210547
Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia., PMID:35120522
Engineering a cell-penetrating hyperstable antibody scFv(Ras) - An extraordinary approach to cancer therapeutics., PMID:34738045
Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC)., PMID:34700281
Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model., PMID:34429319
The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice., PMID:34277420
Probing RAS Function with Monobodies., PMID:33977484
Validation of Isoform- and Mutation-Specific RAS Antibodies., PMID:33977472
Absolute Quantitation of GTPase Protein Abundance., PMID:33977471
NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility., PMID:33960437
RGD4C peptide mediates anti-p21Ras scFv entry into tumor cells and produces an inhibitory effect on the human colon cancer cell line SW480., PMID:33765976
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study., PMID:33753043
PCR Array Technology in Biopsy Samples Identifies Up-Regulated mTOR Pathway Genes as Potential Rejection Biomarkers After Kidney Transplantation., PMID:33681239
Transglutaminase-2, RNA-binding proteins and mitochondrial proteins selectively traffic to MDCK cell-derived microvesicles following H-Ras-induced epithelial-mesenchymal transition., PMID:33638284
Cross-reactivity of NRASQ61R antibody in a subset of Spitz nevi with 11p gain: a potential confounding factor in the era of pathway-based diagnostic approach., PMID:33636207
Enumeration, characterisation and clinicopathological significance of circulating tumour cells in patients with colorectal carcinoma., PMID:33610860
Cx43 phosphorylation sites regulate pancreatic cancer metastasis., PMID:33603164
Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody., PMID:33462327
Magnetic spatiotemporal control of SOS1 coupled nanoparticles for guided neurite growth in dopaminergic single cells., PMID:33384447
Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer., PMID:33162802
For research use only. Not for human or drug use.
